| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
In this study, our challenge was to improve the efficacy of mesenchymal stem cell (MSC)transplantation in vivo by pretreatment of MSCs with HMG-CoA reductase inhibitor. After cardiomyogenic induction in vitro, preteatment with HMG-CoA reductase inhibitor significantly increased the cardio- myogenic transdifferentiation ef ficiency (CTE), which was calculated by immunocytochemistry using anti-cardiac troponin- I antibody. CTE was reduced by pretreatment with HMG-CoA reductase inhibitor and wortmannin, inhibitor of Akt.
|
